Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dianthus Therapeutics (Nasdaq: DNTH) granted inducement equity awards on April 1, 2026, to eight newly hired, non‑executive employees under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Dianthus Therapeutics (Nasdaq: DNTH) granted inducement equity awards on April 1, 2026, to eight newly hired, non‑executive employees under Nasdaq Listing Rule 5635(c)(4).

The awards are non‑qualified stock options for an aggregate of 135,000 shares, with a 10‑year term, $84.56 exercise price, and vesting of 25% after one year then monthly over 36 months; awards were approved by the independent Compensation Committee and are subject to the company equity inducement plan and option agreement.

Argus Apr 7 session

+0.82% close to close Open Argus

Details

News Market Reaction – DNTH

On Apr 7, the first trading day after this news, DNTH closed 0.82% above the previous close.

Data tracked by StockTitan Argus for the Apr 7 session.

Key Figures

Current share price: $86.00 52-week range: $13.37 – $88.49 Shelf registration size: $600,000,000 +5 more

Current share price

$86.00

Pre-news price context

52-week range

$13.37 – $88.49

52-week low and high

Shelf registration size

$600,000,000

S-3 shelf filed 2026-01-28

Inducement option grants

135,000 shares

Non-qualified stock options to new hires

Exercise price

$84.56 per share

Inducement stock options

Option term

10 years

Inducement stock option duration

Initial vesting cliff

25% at 1 year

Inducement option vesting schedule

Remaining vesting period

36 months

Monthly vesting after first anniversary

Historical Context

5 past events · Latest: Mar 12

5 events

1. Mar 12

   Upsized offering close

   24h Move

   -3.1%

   Closing of upsized $719M underwritten public offering with share and warrant issuance.

2. Mar 10

   Offering pricing

   24h Move

   -1.2%

   Pricing of upsized $625M underwritten offering of common shares and pre-funded warrants.

3. Mar 09

   Proposed offering

   24h Move

   +9.7%

   Announcement of proposed $400M underwritten offering with $60M underwriter option.

4. Mar 09

   Earnings & pipeline

   24h Move

   +21.5%

   Phase 3 CAPTIVATE GO decision plus FY 2025 results and detailed pipeline timelines.

5. Mar 09

   Phase 3 GO decision

   24h Move

   +21.5%

   Early GO decision in Phase 3 CAPTIVATE CIDP trial after interim responder analysis.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, exercise price, equity inducement plan

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"The inducement grants were approved ... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"The inducement grants consist of non-qualified stock options to purchase an aggregate of 135,000 shares..."

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

exercise price financial

"...common stock with a 10-year term and an exercise price of $84.56 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

equity inducement plan financial

"The inducement grants are subject to the terms and conditions of the Dianthus Therapeutics, Inc. Equity Inducement Plan..."

An equity inducement plan is a program that gives new hires or targeted employees stock, restricted shares, or stock options as a hiring or retention reward, often separate from the company’s regular long-term incentive plans. Think of it as a signing bonus paid in company stock: it helps attract and keep talent but matters to investors because it can dilute existing shares, change executive incentives, and affect future earnings through compensation expense.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK and WALTHAM, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on April 1, 2026, to eight newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 135,000 shares of the Company's common stock with a 10-year term and an exercise price of $84.56 per share. The options vest as to 25% on the first anniversary of the vesting commencement date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the Dianthus Therapeutics, Inc. Equity Inducement Plan, and the terms and conditions of a stock option agreement.

About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn. 

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Dianthus Therapeutics (DNTH) announce regarding inducement grants on April 6, 2026?

Dianthus announced inducement stock option grants made April 1, 2026 to eight new non‑executive hires. According to the company, the options total 135,000 shares, have a 10‑year term, and an exercise price of $84.56 per share.

How do the DNTH inducement options vest and when does vesting begin?

The options vest 25% on the first anniversary, then monthly over the following 36 months. According to the company, vesting follows the vesting commencement date and continues in equal monthly installments thereafter.

What is the financial term of the DNTH inducement stock options and exercise price?

The inducement options carry a 10‑year term with an exercise price of $84.56 per share. According to the company, the aggregate amount of options granted is 135,000 shares to eight hires.

Under what authority were the DNTH inducement grants approved?

The inducement grants were approved as material inducements under Nasdaq Listing Rule 5635(c)(4). According to the company, the independent Compensation Committee approved the awards consistent with that Nasdaq rule.

Are the DNTH inducement grants subject to any plan or agreement terms?

Yes. The inducement grants are subject to the Dianthus Equity Inducement Plan and individual stock option agreements. According to the company, grant terms and conditions follow those governing documents and agreements.